Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1522828 | 0.94 | MAPK1 (0.41) | MAPK1HSD17B10RXFP1MAPTCYP2C9 | |
| SCHEMBL1523725 | 0.93 | MAPK1 (0.41) | MAPK1HSD17B10RXFP1MAPTCYP2C9 | |
| SCHEMBL1522457 | 0.93 | MAPK1 (0.42) | MAPK1HSD17B10RXFP1MAPTCYP2C9 | |
| SCHEMBL1522557 | 0.92 | MAPK1 (0.50) | MAPK1HSD17B10RXFP1MAPTCYP2C9 | |
| SCHEMBL1522569 | 0.91 | MAPK1 (0.41) | MAPK1HSD17B10RXFP1MAPTCYP2C9 | |
| SCHEMBL1522877 | 0.91 | MAPK1 (0.41) | MAPK1HSD17B10RXFP1MAPTCYP2C9 | |
| SCHEMBL1522687 | 0.91 | MAPK1 (0.40) | MAPK1HSD17B10RXFP1MAPTCYP2C9 | |
| SCHEMBL1523332 | 0.91 | MAPK1 (0.40) | MAPK1HSD17B10RXFP1MAPTCYP2C9 | |
| SCHEMBL1523423 | 0.91 | CYP2C9 (0.41) | MAPK1HSD17B10RXFP1MAPTCYP2C9 | |
| SCHEMBL1523357 | 0.90 | MAPK1 (0.45) | MAPK1HSD17B10RXFP1MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040162285-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-08-19 | — | — | US | claimed |
| US-20040087577-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-05-06 | — | — | US | claimed |
| EP-2361913-A1 | Anti-infective agents | Abbott Laboratories (US) | 2011-08-31 | — | — | EP | disclosed |
| US-7902203-B2 | Anti-infective agents | ABBOTT LABORATORIES, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-1560827-B1 | ANTI-INFECTIVE AGENTS | ABBOTT LAB (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20050075331-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2005-04-07 | — | — | US | disclosed |
| US-20040167123-A1 | Anti-infective agents | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040162285-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-08-19 | — | — | US | disclosed |
| US-20040087577-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162285-A1 | Anti-infective agents | POLR1C, RPL5, POLB | MAPK1 1456/4885HSD17B10 1232/4885RXFP1 4826/4885 |
| US-20040167123-A1 | Anti-infective agents | SERPINB1, CYP51A1, ZC3HAV1 | MAPK1 739/4885HSD17B10 1422/4885RXFP1 4401/4885 |
| US-20050075331-A1 | Anti-infective agents | RPL35, POLI, POLRMT | MAPK1 2328/4885HSD17B10 1335/4885RXFP1 4727/4885 |
| US-20040087577-A1 | Anti-infective agents | POLR1C, RPL5, POLB | MAPK1 1456/4885HSD17B10 1232/4885RXFP1 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.